Adjunctive rufinamide in Lennox-Gastaut syndrome

A long-term, open-label extension study

G. Kluger, T. Glauser, Gregory Krauss, R. Seeruthun, C. Perdomo, S. Arroyo

Research output: Contribution to journalArticle

Abstract

Objective - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study. Materials and methods - In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide ∼25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests. Results - Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had ≥50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%). Conclusions - In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.

Original languageEnglish (US)
Pages (from-to)202-208
Number of pages7
JournalActa Neurologica Scandinavica
Volume122
Issue number3
DOIs
StatePublished - Sep 2010

Fingerprint

Seizures
Double-Blind Method
Anticonvulsants
Vomiting
Young Adult
Fever
Therapeutics
Lennox Gastaut Syndrome
rufinamide

Keywords

  • epilepsy
  • extension study
  • Lennox-Gastaut syndrome
  • open-label
  • rufinamide
  • tonic-atonic seizures
  • total seizures

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Adjunctive rufinamide in Lennox-Gastaut syndrome : A long-term, open-label extension study. / Kluger, G.; Glauser, T.; Krauss, Gregory; Seeruthun, R.; Perdomo, C.; Arroyo, S.

In: Acta Neurologica Scandinavica, Vol. 122, No. 3, 09.2010, p. 202-208.

Research output: Contribution to journalArticle

Kluger, G. ; Glauser, T. ; Krauss, Gregory ; Seeruthun, R. ; Perdomo, C. ; Arroyo, S. / Adjunctive rufinamide in Lennox-Gastaut syndrome : A long-term, open-label extension study. In: Acta Neurologica Scandinavica. 2010 ; Vol. 122, No. 3. pp. 202-208.
@article{dcddae24649c4c72919a928617d1d9f1,
title = "Adjunctive rufinamide in Lennox-Gastaut syndrome: A long-term, open-label extension study",
abstract = "Objective - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study. Materials and methods - In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide ∼25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests. Results - Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0{\%} and 47.9{\%} of patients had ≥50{\%} reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6{\%}) and pyrexia (25.8{\%}). Conclusions - In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.",
keywords = "epilepsy, extension study, Lennox-Gastaut syndrome, open-label, rufinamide, tonic-atonic seizures, total seizures",
author = "G. Kluger and T. Glauser and Gregory Krauss and R. Seeruthun and C. Perdomo and S. Arroyo",
year = "2010",
month = "9",
doi = "10.1111/j.1600-0404.2010.01334.x",
language = "English (US)",
volume = "122",
pages = "202--208",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Adjunctive rufinamide in Lennox-Gastaut syndrome

T2 - A long-term, open-label extension study

AU - Kluger, G.

AU - Glauser, T.

AU - Krauss, Gregory

AU - Seeruthun, R.

AU - Perdomo, C.

AU - Arroyo, S.

PY - 2010/9

Y1 - 2010/9

N2 - Objective - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study. Materials and methods - In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide ∼25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests. Results - Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had ≥50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%). Conclusions - In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.

AB - Objective - This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study. Materials and methods - In total, 124 patients (aged 4-37 years), receiving 1-3 concomitant antiepileptic drugs, were treated with rufinamide ∼25-60 mg/kg/day. Efficacy was assessed by seizure frequency; tolerability by adverse events (AEs) and laboratory tests. Results - Overall, patients were treated with rufinamide for a median (range) of 432 (10-1149) days. Reductions in seizure frequency were observed throughout the study; during the last 12 months of treatment, 41.0% and 47.9% of patients had ≥50% reduction in total and tonic-atonic seizure frequency, respectively. The most common AEs were vomiting (30.6%) and pyrexia (25.8%). Conclusions - In this open-label extension, rufinamide appeared to be an effective long-term adjunctive therapy for the treatment of LGS-associated seizures in children and young adults.

KW - epilepsy

KW - extension study

KW - Lennox-Gastaut syndrome

KW - open-label

KW - rufinamide

KW - tonic-atonic seizures

KW - total seizures

UR - http://www.scopus.com/inward/record.url?scp=77955298453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955298453&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0404.2010.01334.x

DO - 10.1111/j.1600-0404.2010.01334.x

M3 - Article

VL - 122

SP - 202

EP - 208

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 3

ER -